{"success":true,"data":{"pressRelease":{"id":"119348","rtpr_id":"nGNX4D0rjR","ticker":"SCNX","exchange":"NASDAQ","all_tickers":["SCNX"],"title":"SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance","author":"Globe Newswire","published_at":"2026-08-14T12:08:00.298Z","article_body":"Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing\nCommercial Revenue Base\n\nQ2 2026 Operating Loss Improved Approximately 48% Year-over-Year to\nApproximately $2.7 Million\n\nQ2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately\n$2.8 Million\n\nCommenced Commercial Launch of REZENOPY™, Establishing the Company’s\nSecond Commercial Product and Expanding Its Revenue-Generating Portfolio\n\nCOMMACK, NY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC.\n(NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned\npharmaceutical operating companies focused on providing enhanced value to\npatients, physicians and caregivers through the development,\ncommercialization, and distribution of novel specialty products that address\nunmet market needs, today provided a business update and reported financial\nresults for the three and six months ended June 30, 2026.\n\nSecond Quarter 2026 and First Half 2026 Financial Highlights\n* Revenue increased approximately 510% sequentially to $343,639 in Q2 2026,\ncompared with $56,325 in Q1 2026.\n* First-half 2026 revenue increased significantly year-over-year to $399,964,\ncompared with $10,258 for the first six months of 2025.\n* Q2 2026 gross profit was $335,779, compared to $0 in Q2 2025, with Q2 2026\ngross margin being approximately 97.7%.\n* First-half 2026 gross profit increased to $389,629, compared with $673 for\nthe first six months of 2025, with a gross margin of approximately 97.4% for\nthe first half of 2026.\n* Q2 2026 operating expenses decreased approximately 41% year-over-year to\napproximately $3.0 million, compared with approximately $5.2 million in Q2\n2025, demonstrating continued expense management and operating discipline.\n* First-half 2026 operating expenses decreased approximately 24% to about $6.6\nmillion, compared with approximately $8.7 million during the first six months\nof 2025.\n* Q2 2026 operating loss improved approximately 48% to about $2.7 million,\ncompared with an operating loss of approximately $5.2 million in Q2 2025.\n* Q2 2026 net loss narrowed approximately 58% to about $2.8 million, compared\nwith a net loss of approximately $6.7 million in Q2 2025. Basic and diluted\nnet loss per share improved to $0.07 from $0.48 during that time.\n* First-half 2026 net loss narrowed approximately 36% to about $6.2 million,\ncompared with approximately $9.8 million for the first six months of 2025.\nBasic and diluted net loss per share improved to $0.16 from $0.83 during that\ntime.\n* As of June 30, 2026, the Company had cash, cash equivalents and restricted\ncash of approximately $11.2 million compared to approximately $6.7 million of\ncash and cash equivalents as of December 31, 2025.\nKey Operational Highlights in Q2 2026 and Subsequent Events:\n* United States Patent and Trademark Office (USPTO) granted a second patent\ncovering REZENOPY(™) (naloxone hydrochloride) Nasal Spray 10 mg,\nstrengthening intellectual property protection for the product through 2041.\n* United States Patent and Trademark Office (USPTO) granted a third patent\ncovering Arbli(™) (losartan potassium) oral suspension, further\nstrengthening the product’s intellectual property portfolio and extending\nexpected market exclusivity through 2041.\n* Secured formulary coverage for REZENOPY(™) with a large national health\nplan and expanded the commercial team to support market penetration and\ngrowth.\n* Expanded ARBLI(™) payer coverage and commercial access, adding\napproximately 12.5 million covered lives.\n* Commenced the commercial launch of REZENOPY(™) and began fulfillment of\ninitial purchase orders, marking an important milestone in the Company's\ncommercialization strategy.\nNarasimhan Mani, President, Interim CFO, and Co-CEO of Scienture, commented,\n“We believe our second-quarter results demonstrate that Scienture has\nreached an important inflection point. Revenue for Q2 20226 increased about\n510% sequentially, from approximately $56,000 in the first quarter to\napproximately $344,000 in the second quarter. At the same time, we generated\ngross margins of approximately 98%, reduced operating expenses by about 41%\nyear-over-year and narrowed our net loss by approximately 58%. We also ended\nthe quarter with approximately $11.2 million in cash, cash equivalents and\nrestricted cash, compared with about $6.7 million at year-end 2025, providing\nus with a stronger financial position as we execute the next phase of our\ncommercial growth strategy. We believe these results demonstrate that we are\non the right path to deliver value added business growth in the coming\nquarters and that we are beginning to realize the operating leverage we have\nbeen working toward.”\n\n“Arbli’s continued commercial progress gives us confidence in our ability\nto build and scale differentiated pharmaceutical products, and we believe we\nhave only begun to realize its market opportunity,” stated Shankar\nHariharan, Executive Chairman and co-CEO of Scienture. “We are expanding\npayer access and commercial availability for Arbli(™) while simultaneously\nbringing REZENOPY(™) online commercially in the third quarter of 2026. With\nArbli(™) continuing to gain traction and REZENOPY(™) becoming our second\ncommercial-stage product, we believe Scienture is positioned to meaningfully\naccelerate top-line revenue growth during the second half of 2026 and into\n2027. With two differentiated FDA-approved products, approximately 98% gross\nmargins, a strengthened cash position and a more disciplined operating expense\nstructure, we believe we have turned an important corner and established a\nclear path toward our goal of achieving profitability in 2027.”\n\nAbout Arbli(™)\n\nArbli™ is a novel proprietary formulation of losartan, a widely prescribed\nangiotensin receptor blocker (ARB) for hypertension. It is the first and only\nliquid formulation of losartan on the market that does not require compounding\nand has reduced dosing volume and long-term shelf life at room temperature\nstorage. Arbli(™) is FDA-approved for the treatment of hypertension in\npatients greater than six years old, for reducing the risk of stroke in\npatients with hypertension and left ventricular hypertrophy, and for treating\ndiabetic nephropathy in certain patients with type 2 diabetes. By offering a\nsafe, effective, and convenient liquid alternative, Arbli(™) provides a\ntailored solution for patients who require or prefer a liquid formulation. As\nan FDA-approved product, Arbli(™) provides consistent quality and dosing\naccuracy, addressing the risks and inconsistencies often associated with\nextemporaneously compounded losartan prescriptions. Arbli(™) has two issued\npatents from the USPTO, which are also listed in the FDA Orangebook.\n\nArbli(™) is the first and only oral liquid formulation of losartan approved\nby the U.S. FDA. Arbli(™) comes in a 165 mL bottle as a peppermint flavored\nsuspension that does not require refrigeration and has been approved for a\nshelf life of 24 months from the date of manufacture when stored at room\ntemperature.\n\nINDICATION\n\nArbli(™) is an angiotensin II receptor blocker (ARB) indicated for:\n* Treatment of hypertension, to lower blood pressure in adults and children\ngreater than 6 years old. Lowering blood pressure reduces the risk of fatal\nand nonfatal cardiovascular events, primarily strokes and myocardial\ninfarctions.\n\n* Reduction of the risk of stroke in patients with hypertension and left\nventricular hypertrophy.\n\n* Treatment of diabetic nephropathy with an elevated serum creatinine and\nproteinuria in patients with type 2 diabetes and a history of hypertension.\nIMPORTANT SAFETY INFORMATION\n* Do not take Arbli(™) when pregnant. When pregnancy is detected,\ndiscontinue Arbli(™) as soon as possible. Drugs that act directly on the\nrenin-angiotensin system can cause injury and death to the developing fetus.\nArbli(™) can cause fetal harm when administered to a pregnant woman. Use of\ndrugs that act on the renin-angiotensin system during the second and third\ntrimesters of pregnancy reduces fetal renal function and increases fetal and\nneonatal morbidity and death.\n\n* Do not co-administer Arbli(™) with aliskiren in patients with diabetes.\nAvoid use of aliskiren with Arbli(™) in patients with renal impairment (GFR\n<60 mL/min).\n\n* Do not administer Arbli(™) in patients with severe hepatic impairment.\nArbli(™) has not been studied in patients with severe hepatic impairment.\n\n* The most common adverse reactions are (incidence ≥2% and greater than\nplacebo): dizziness, upper respiratory infection, nasal congestion, and back\npain.\nYou are encouraged to report negative side effects of prescription drugs to\nthe FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also\ncontact Scienture at 1-833-754-4917.\n\nPlease see the full Prescribing Information for complete product information.\nFor more information, talk to your healthcare provider.\n\nAbout Hypertension\n\nHypertension (high blood pressure) is a cardiovascular condition, when the\npressure in the blood vessels is too high (140/90 mmHg or higher). According\nto the CDC, hypertension, or high blood pressure, affects nearly half of\nadults in the United States, or approximately 119.9 million people.\nHypertension is defined as a systolic blood pressure of 140 mmHg or higher,\nand diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk\nfactor for stroke and heart disease, which are leading causes of death in the\nU.S. Factors that increase the risk of having high blood pressure include:\nolder age, genetics, being overweight or obese, not being physically active,\nhigh-salt diet and drinking too much alcohol. Hypertension is clinically\ndiagnosed if, when blood pressure is measured on two different days, the\nsystolic blood pressure readings on both days is ≥140 mmHg and/or the\ndiastolic blood pressure readings on both days is ≥ 90 mmHg.\n\nAbout REZENOPY(™)\n\nREZENOPY(™) (naloxone hydrochloride) Nasal Spray 10mg, is indicated for the\nemergency treatment of known or suspected opioid overdose, as manifested by\nrespiratory and/or central nervous system depression in adult and pediatric\npatients. REZENOPY(™) nasal spray is not a substitute for emergency medical\ncare. If the desired response is not obtained after 2 to 3 minutes, administer\na second dose of REZENOPY(™) nasal spray using a new REZENOPY(™) nasal\nspray device. If there is still no response and additional doses are\navailable, administer additional doses of REZENOPY(™) every 2 to 3 minutes,\nalternating nostrils and using a new REZENOPY(™), until emergency medical\nassistance arrives. Additional supportive and/or resuscitative measures may be\nhelpful while awaiting emergency medical assistance \n\nREZENOPY(™) nasal spray is for intranasal use only and is supplied as a\ncarton containing two (2) blister packages each with a single spray device.\n\nIMPORTANT SAFETY INFORMATION\n\nREZENOPY(™) (naloxone hydrochloride) Nasal Spray 10 mg is an opioid\nantagonist indicated for the emergency treatment of known or suspected opioid\noverdose, as manifested by respiratory and/or central nervous system\ndepression in adult and pediatric patients. It is intended for immediate\nadministration as emergency therapy in settings where opioids may be present\nand is not a substitute for emergency medical care.\n\nImportant Safety Information\n* Contraindications: REZENOPY(™) nasal spray is contraindicated in patients\nknown to be hypersensitive to naloxone hydrochloride or to any of the other\ningredients.\n\n* Warnings and Precautions:\n\n * Risk of Recurrent Respiratory and CNS Depression: Due to the duration of\naction of naloxone relative to the opioid, keep the patient under continued\nsurveillance and administer additional doses as necessary while awaiting\nemergency medical assistance.\n\n* Risk of Limited Efficacy with Partial Agonists or Mixed\nAgonists/Antagonists: Reversal of respiratory depression caused by partial\nagonists or mixed agonists/antagonists, such as buprenorphine and pentazocine,\nmay be incomplete. Larger or repeat doses may be required.\n\n* Precipitation of Severe Opioid Withdrawal: Use in patients who are\nopioid-dependent may precipitate opioid withdrawal. In neonates, opioid\nwithdrawal may be life-threatening if not recognized and properly treated.\nMonitor for the development of opioid withdrawal.\n\n* Risk of Cardiovascular Effects: Abrupt postoperative reversal of opioid\ndepression may result in adverse cardiovascular effects. These events have\nprimarily occurred in patients who had pre-existing cardiovascular disorders\nor received other drugs that may have similar adverse cardiovascular effects.\nMonitor these patients closely in an appropriate healthcare setting after use\nof naloxone hydrochloride.\n\n\n \n* Adverse Reactions: The following adverse reactions were observed in a\nREZENOPY(™ )nasal spray clinical study: upper abdominal pain,\nnasopharyngitis, and dysgeusia.\nFor complete product information, including Patient Information, please refer\nto the full Prescribing Information.\n\nAbout Scienture Holdings, Inc.\n\nSCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary,\nScienture, LLC, is a comprehensive pharmaceutical product company focused on\nproviding enhanced value to patients, physicians and caregivers by offering\nnovel specialty products to satisfy unmet market needs. Scienture, LLC is a\nbranded, specialty pharmaceutical company consisting of a highly experienced\nteam of industry professionals who are passionate about developing and\nbringing to market unique specialty products that provide enhanced value to\npatients and healthcare systems. The assets in development at Scienture are\nacross therapeutics areas, indications and cater to different market segments\nand channels. For more information please visit: www.scientureholdings.com and\nwww.scienture.com.\n\nCautionary Statements Regarding Forward-Looking Statements\n\nThis press release contains certain statements that may be deemed to be\n“forward-looking statements” within the federal securities laws, including\nthe safe harbor provisions under the Private Securities Litigation Reform Act\nof 1995. Statements that are not historical are forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933 and Section\n21E of the Securities Exchange Act of 1934. Forward-looking statements relate\nto future events or our future performance or future financial condition.\nThese forward-looking statements are not historical facts, but rather are\nbased on current expectations, estimates and projections about our company,\nour industry, our beliefs and our assumptions. Such forward-looking statements\ninclude, but are not limited to, statements regarding our or our management\nteam’s expectations, hopes, beliefs, intentions or strategies regarding the\nfuture, including for the products we may launch, the success those products\nmay have in the marketplace, such as Arbli™ and REZENOPY™, and our\nstrategies related to those products. In addition, any statements that refer\nto projections, forecasts or other characterizations of future events or\ncircumstances, including any underlying assumptions, are forward-looking\nstatements. In some cases, you can identify forward-looking statements by the\nfollowing words: “anticipate,” “believe,” “continue,” “could,”\n“estimate,” “expect,” “intend,” “may,” “ongoing,”\n“plan,” “potential,” “predict,” “project,” “should,” or\nthe negative of these terms or other similar expressions, but the absence of\nthese words does not mean that a statement is not forward-looking.\nForward-looking statements are subject to a number of risks and uncertainties\n(some of which are beyond our control) that may cause actual results or\nperformance to be materially different from those expressed or implied by such\nforward-looking statements. Accordingly, readers should not place undue\nreliance on any forward-looking statements. These risks include risks relating\nto agreements with third parties; our ability to raise funding in the future,\nas needed, and the terms of such funding, including potential dilution caused\nthereby; our ability to continue as a going concern; security interests under\ncertain of our credit arrangements; our ability to maintain the listing of our\ncommon stock on the Nasdaq Stock Market LLC; claims relating to alleged\nviolations of intellectual property rights of others; the outcome of any\ncurrent legal proceedings or future legal proceedings that may be instituted\nagainst us; unanticipated difficulties or expenditures relating to our\nbusiness plan; and those risks detailed in our most recent Annual Report on\nForm 10-K, as amended, and subsequent reports filed with the Securities and\nExchange Commission.\n\nForward-looking statements speak only as of the date they are made. Scienture\nHoldings, Inc. undertakes no obligation to update or revise any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise that occur after that date, except as otherwise provided\nby law.\n\nContact:\n\nSCIENTURE HOLDINGS, INC.\n20 Austin Blvd\nCommack, NY 11725\nEmail: IR@Scienture.com\n\n Scienture Holdings, Inc. formerly TRxADE HEALTH, INC.\nCondensed Consolidated Balance Sheets\nAs of June 30, 2026 and December 31, 2025\n(Unaudited)\n\n June 30, 2026 December 31, 2025 \n ASSETS \n Current assets: \n Cash and cash equivalents $ 8,188,140 $ 6,662,008 \n Accounts receivable, net 385,313 731,328 \n Inventory 203,074 213,408 \n Prepaid expenses 425,370 262,278 \n Deferred offering costs - 47,384 \n Total current assets 9,201,897 7,916,406 \n Restricted cash 3,012,271 - \n Property, plant and equipment, net 14,500 15,500 \n Notes receivable 5,000,000 5,000,000 \n Interest receivable 437,500 250,000 \n Intangible assets, net 70,065,371 70,973,064 \n Operating lease right-of-use assets 2,468 23,360 \n Total assets $ 87,734,007 $ 84,178,330 \n \n LIABILITIES AND STOCKHOLDERS’ EQUITY \n Current liabilities: \n Accounts payable $ 916,771 $ 1,443,266 \n Accrued liabilities 503,634 657,034 \n Operating lease liability - current 2,546 24,137 \n Warrant liability - 10,914 \n Note payable, net of debt discount - current portion 1,118,349 - \n Development agreement liability - current portion 485,000 600,000 \n Total current liabilities 3,026,300 2,735,351 \n Note payable, net of debt discount 9,568,586 - \n Development agreement liability - 285,000 \n Deferred tax liability 11,037,595 11,037,595 \n Total liabilities 23,632,481 14,057,946 \n \n Commitments and contingencies (Note 13) \n \n Stockholders’ equity: \n Series A preferred stock, $0.00001 par value; 0 and 9,211,246 shares authorized; 0 shares issued and outstanding as of both June 30, 2026 and December 31, 2025 - - \n Series B preferred stock, $0.00001 par value; 787,754 shares authorized; 15,759 shares issued and outstanding as of both June 30, 2026 and December 31, 2025 - - \n Series C preferred stock, $0.00001 par value; 1,000 shares authorized; 0 shares issued and outstanding as of both June 30, 2026 and December 31, 2025 - - \n Series X preferred stock, $0.00001 par value; 9,211,246 shares authorized; 0 shares issued and outstanding as of both June 30, 2026 and December 31, 2025 - - \n \n Common stock, $0.00001 par value; 100,000,000 shares authorized; 41,064,146 and 40,630,815 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively 1,448,331 and 1,015,000 shares unvested as of June 30, 2026 and December 31, 2025, respectively 410 406 \n Additional paid-in capital 150,876,988 150,671,215 \n Accumulated deficit (86,775,872 ) (80,551,237 ) \n Total stockholders’ equity 64,101,526 70,120,384 \n Total liabilities and stockholders’ equity $ 87,734,007 $ 84,178,330 \n\nScienture Holdings, Inc. formerly TRxADE HEALTH, INC.\nCondensed Consolidated Statements Of Operations\nFor the Three and Six Months Ended June 30, 2026 and 2025\n(Unaudited)\n\n \n Three Months Ended Six Months Ended \n June 30, June 30, \n 2026 2025 2026 2025 \n Revenues $ 343,639 $ - $ 399,964 $ 10,258 \n Cost of sales 7,860 - 10,335 9,585 \n Gross profit 335,779 - 389,629 673 \n \n Operating expenses: \n Wage and salary expense 411,411 773,739 831,419 1,469,807 \n Professional fees 963,752 209,763 1,896,304 622,613 \n Accounting and legal expense 117,815 381,683 443,993 852,508 \n Technology expense 7,139 21,408 22,902 83,028 \n General and administrative 368,790 2,927,764 1,443,654 4,283,712 \n Research and development 1,166,605 843,549 1,960,589 1,418,228 \n Total operating expenses 3,035,512 5,157,906 6,598,861 8,729,896 \n Operating loss (2,699,733 ) (5,157,906 ) (6,209,232 ) (8,729,223 ) \n \n Non-operating income (expense): \n Change in fair value of warrant liability - 76,122 10,910 722,108 \n Change in fair value of derivative liability - (662,916 ) - (59,594 ) \n Loss on conversion of note payable - - - (96,646 ) \n Loss on disposition of subsidiaries - (385,528 ) - (385,528 ) \n Interest income 147,147 63,148 280,491 88,590 \n Interest expense (269,785 ) (653,493 ) (306,804 ) (1,324,277 ) \n Total non-operating expense (122,638 ) (1,562,667 ) (15,403 ) (1,055,347 ) \n \n Benefit (provision) for income taxes - - - - \n Net loss $ (2,822,371 ) $ (6,720,573 ) $ (6,224,635 ) $ (9,784,570 ) \n \n Net loss per common share \n Basic $ (0.07 ) $ (0.48 ) $ (0.16 ) $ (0.83 ) \n Diluted $ (0.07 ) $ (0.48 ) $ (0.16 ) $ (0.83 ) \n Weighted average common shares outstanding \n Basic 39,615,815 14,141,443 39,615,815 11,844,024 \n Diluted 39,615,815 14,141,443 39,615,815 11,844,024 \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1f177940-bb59-4f95-a316-0ca68e549ea4)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4D0rjR","title":"SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance","author":"Globe Newswire","ticker":"SCNX","created":"2026-08-14T12:08:00.298Z","tickers":["SCNX"],"exchange":"NASDAQ","article_body":"Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing\nCommercial Revenue Base\n\nQ2 2026 Operating Loss Improved Approximately 48% Year-over-Year to\nApproximately $2.7 Million\n\nQ2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately\n$2.8 Million\n\nCommenced Commercial Launch of REZENOPY™, Establishing the Company’s\nSecond Commercial Product and Expanding Its Revenue-Generating Portfolio\n\nCOMMACK, NY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC.\n(NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned\npharmaceutical operating companies focused on providing enhanced value to\npatients, physicians and caregivers through the development,\ncommercialization, and distribution of novel specialty products that address\nunmet market needs, today provided a business update and reported financial\nresults for the three and six months ended June 30, 2026.\n\nSecond Quarter 2026 and First Half 2026 Financial Highlights\n* Revenue increased approximately 510% sequentially to $343,639 in Q2 2026,\ncompared with $56,325 in Q1 2026.\n* First-half 2026 revenue increased significantly year-over-year to $399,964,\ncompared with $10,258 for the first six months of 2025.\n* Q2 2026 gross profit was $335,779, compared to $0 in Q2 2025, with Q2 2026\ngross margin being approximately 97.7%.\n* First-half 2026 gross profit increased to $389,629, compared with $673 for\nthe first six months of 2025, with a gross margin of approximately 97.4% for\nthe first half of 2026.\n* Q2 2026 operating expenses decreased approximately 41% year-over-year to\napproximately $3.0 million, compared with approximately $5.2 million in Q2\n2025, demonstrating continued expense management and operating discipline.\n* First-half 2026 operating expenses decreased approximately 24% to about $6.6\nmillion, compared with approximately $8.7 million during the first six months\nof 2025.\n* Q2 2026 operating loss improved approximately 48% to about $2.7 million,\ncompared with an operating loss of approximately $5.2 million in Q2 2025.\n* Q2 2026 net loss narrowed approximately 58% to about $2.8 million, compared\nwith a net loss of approximately $6.7 million in Q2 2025. Basic and diluted\nnet loss per share improved to $0.07 from $0.48 during that time.\n* First-half 2026 net loss narrowed approximately 36% to about $6.2 million,\ncompared with approximately $9.8 million for the first six months of 2025.\nBasic and diluted net loss per share improved to $0.16 from $0.83 during that\ntime.\n* As of June 30, 2026, the Company had cash, cash equivalents and restricted\ncash of approximately $11.2 million compared to approximately $6.7 million of\ncash and cash equivalents as of December 31, 2025.\nKey Operational Highlights in Q2 2026 and Subsequent Events:\n* United States Patent and Trademark Office (USPTO) granted a second patent\ncovering REZENOPY(™) (naloxone hydrochloride) Nasal Spray 10 mg,\nstrengthening intellectual property protection for the product through 2041.\n* United States Patent and Trademark Office (USPTO) granted a third patent\ncovering Arbli(™) (losartan potassium) oral suspension, further\nstrengthening the product’s intellectual property portfolio and extending\nexpected market exclusivity through 2041.\n* Secured formulary coverage for REZENOPY(™) with a large national health\nplan and expanded the commercial team to support market penetration and\ngrowth.\n* Expanded ARBLI(™) payer coverage and commercial access, adding\napproximately 12.5 million covered lives.\n* Commenced the commercial launch of REZENOPY(™) and began fulfillment of\ninitial purchase orders, marking an important milestone in the Company's\ncommercialization strategy.\nNarasimhan Mani, President, Interim CFO, and Co-CEO of Scienture, commented,\n“We believe our second-quarter results demonstrate that Scienture has\nreached an important inflection point. Revenue for Q2 20226 increased about\n510% sequentially, from approximately $56,000 in the first quarter to\napproximately $344,000 in the second quarter. At the same time, we generated\ngross margins of approximately 98%, reduced operating expenses by about 41%\nyear-over-year and narrowed our net loss by approximately 58%. We also ended\nthe quarter with approximately $11.2 million in cash, cash equivalents and\nrestricted cash, compared with about $6.7 million at year-end 2025, providing\nus with a stronger financial position as we execute the next phase of our\ncommercial growth strategy. We believe these results demonstrate that we are\non the right path to deliver value added business growth in the coming\nquarters and that we are beginning to realize the operating leverage we have\nbeen working toward.”\n\n“Arbli’s continued commercial progress gives us confidence in our ability\nto build and scale differentiated pharmaceutical products, and we believe we\nhave only begun to realize its market opportunity,” stated Shankar\nHariharan, Executive Chairman and co-CEO of Scienture. “We are expanding\npayer access and commercial availability for Arbli(™) while simultaneously\nbringing REZENOPY(™) online commercially in the third quarter of 2026. With\nArbli(™) continuing to gain traction and REZENOPY(™) becoming our second\ncommercial-stage product, we believe Scienture is positioned to meaningfully\naccelerate top-line revenue growth during the second half of 2026 and into\n2027. With two differentiated FDA-approved products, approximately 98% gross\nmargins, a strengthened cash position and a more disciplined operating expense\nstructure, we believe we have turned an important corner and established a\nclear path toward our goal of achieving profitability in 2027.”\n\nAbout Arbli(™)\n\nArbli™ is a novel proprietary formulation of losartan, a widely prescribed\nangiotensin receptor blocker (ARB) for hypertension. It is the first and only\nliquid formulation of losartan on the market that does not require compounding\nand has reduced dosing volume and long-term shelf life at room temperature\nstorage. Arbli(™) is FDA-approved for the treatment of hypertension in\npatients greater than six years old, for reducing the risk of stroke in\npatients with hypertension and left ventricular hypertrophy, and for treating\ndiabetic nephropathy in certain patients with type 2 diabetes. By offering a\nsafe, effective, and convenient liquid alternative, Arbli(™) provides a\ntailored solution for patients who require or prefer a liquid formulation. As\nan FDA-approved product, Arbli(™) provides consistent quality and dosing\naccuracy, addressing the risks and inconsistencies often associated with\nextemporaneously compounded losartan prescriptions. Arbli(™) has two issued\npatents from the USPTO, which are also listed in the FDA Orangebook.\n\nArbli(™) is the first and only oral liquid formulation of losartan approved\nby the U.S. FDA. Arbli(™) comes in a 165 mL bottle as a peppermint flavored\nsuspension that does not require refrigeration and has been approved for a\nshelf life of 24 months from the date of manufacture when stored at room\ntemperature.\n\nINDICATION\n\nArbli(™) is an angiotensin II receptor blocker (ARB) indicated for:\n* Treatment of hypertension, to lower blood pressure in adults and children\ngreater than 6 years old. Lowering blood pressure reduces the risk of fatal\nand nonfatal cardiovascular events, primarily strokes and myocardial\ninfarctions.\n\n* Reduction of the risk of stroke in patients with hypertension and left\nventricular hypertrophy.\n\n* Treatment of diabetic nephropathy with an elevated serum creatinine and\nproteinuria in patients with type 2 diabetes and a history of hypertension.\nIMPORTANT SAFETY INFORMATION\n* Do not take Arbli(™) when pregnant. When pregnancy is detected,\ndiscontinue Arbli(™) as soon as possible. Drugs that act directly on the\nrenin-angiotensin system can cause injury and death to the developing fetus.\nArbli(™) can cause fetal harm when administered to a pregnant woman. Use of\ndrugs that act on the renin-angiotensin system during the second and third\ntrimesters of pregnancy reduces fetal renal function and increases fetal and\nneonatal morbidity and death.\n\n* Do not co-administer Arbli(™) with aliskiren in patients with diabetes.\nAvoid use of aliskiren with Arbli(™) in patients with renal impairment (GFR\n<60 mL/min).\n\n* Do not administer Arbli(™) in patients with severe hepatic impairment.\nArbli(™) has not been studied in patients with severe hepatic impairment.\n\n* The most common adverse reactions are (incidence ≥2% and greater than\nplacebo): dizziness, upper respiratory infection, nasal congestion, and back\npain.\nYou are encouraged to report negative side effects of prescription drugs to\nthe FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also\ncontact Scienture at 1-833-754-4917.\n\nPlease see the full Prescribing Information for complete product information.\nFor more information, talk to your healthcare provider.\n\nAbout Hypertension\n\nHypertension (high blood pressure) is a cardiovascular condition, when the\npressure in the blood vessels is too high (140/90 mmHg or higher). According\nto the CDC, hypertension, or high blood pressure, affects nearly half of\nadults in the United States, or approximately 119.9 million people.\nHypertension is defined as a systolic blood pressure of 140 mmHg or higher,\nand diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk\nfactor for stroke and heart disease, which are leading causes of death in the\nU.S. Factors that increase the risk of having high blood pressure include:\nolder age, genetics, being overweight or obese, not being physically active,\nhigh-salt diet and drinking too much alcohol. Hypertension is clinically\ndiagnosed if, when blood pressure is measured on two different days, the\nsystolic blood pressure readings on both days is ≥140 mmHg and/or the\ndiastolic blood pressure readings on both days is ≥ 90 mmHg.\n\nAbout REZENOPY(™)\n\nREZENOPY(™) (naloxone hydrochloride) Nasal Spray 10mg, is indicated for the\nemergency treatment of known or suspected opioid overdose, as manifested by\nrespiratory and/or central nervous system depression in adult and pediatric\npatients. REZENOPY(™) nasal spray is not a substitute for emergency medical\ncare. If the desired response is not obtained after 2 to 3 minutes, administer\na second dose of REZENOPY(™) nasal spray using a new REZENOPY(™) nasal\nspray device. If there is still no response and additional doses are\navailable, administer additional doses of REZENOPY(™) every 2 to 3 minutes,\nalternating nostrils and using a new REZENOPY(™), until emergency medical\nassistance arrives. Additional supportive and/or resuscitative measures may be\nhelpful while awaiting emergency medical assistance \n\nREZENOPY(™) nasal spray is for intranasal use only and is supplied as a\ncarton containing two (2) blister packages each with a single spray device.\n\nIMPORTANT SAFETY INFORMATION\n\nREZENOPY(™) (naloxone hydrochloride) Nasal Spray 10 mg is an opioid\nantagonist indicated for the emergency treatment of known or suspected opioid\noverdose, as manifested by respiratory and/or central nervous system\ndepression in adult and pediatric patients. It is intended for immediate\nadministration as emergency therapy in settings where opioids may be present\nand is not a substitute for emergency medical care.\n\nImportant Safety Information\n* Contraindications: REZENOPY(™) nasal spray is contraindicated in patients\nknown to be hypersensitive to naloxone hydrochloride or to any of the other\ningredients.\n\n* Warnings and Precautions:\n\n * Risk of Recurrent Respiratory and CNS Depression: Due to the duration of\naction of naloxone relative to the opioid, keep the patient under continued\nsurveillance and administer additional doses as necessary while awaiting\nemergency medical assistance.\n\n* Risk of Limited Efficacy with Partial Agonists or Mixed\nAgonists/Antagonists: Reversal of respiratory depression caused by partial\nagonists or mixed agonists/antagonists, such as buprenorphine and pentazocine,\nmay be incomplete. Larger or repeat doses may be required.\n\n* Precipitation of Severe Opioid Withdrawal: Use in patients who are\nopioid-dependent may precipitate opioid withdrawal. In neonates, opioid\nwithdrawal may be life-threatening if not recognized and properly treated.\nMonitor for the development of opioid withdrawal.\n\n* Risk of Cardiovascular Effects: Abrupt postoperative reversal of opioid\ndepression may result in adverse cardiovascular effects. These events have\nprimarily occurred in patients who had pre-existing cardiovascular disorders\nor received other drugs that may have similar adverse cardiovascular effects.\nMonitor these patients closely in an appropriate healthcare setting after use\nof naloxone hydrochloride.\n\n\n \n* Adverse Reactions: The following adverse reactions were observed in a\nREZENOPY(™ )nasal spray clinical study: upper abdominal pain,\nnasopharyngitis, and dysgeusia.\nFor complete product information, including Patient Information, please refer\nto the full Prescribing Information.\n\nAbout Scienture Holdings, Inc.\n\nSCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary,\nScienture, LLC, is a comprehensive pharmaceutical product company focused on\nproviding enhanced value to patients, physicians and caregivers by offering\nnovel specialty products to satisfy unmet market needs. Scienture, LLC is a\nbranded, specialty pharmaceutical company consisting of a highly experienced\nteam of industry professionals who are passionate about developing and\nbringing to market unique specialty products that provide enhanced value to\npatients and healthcare systems. The assets in development at Scienture are\nacross therapeutics areas, indications and cater to different market segments\nand channels. For more information please visit: www.scientureholdings.com and\nwww.scienture.com.\n\nCautionary Statements Regarding Forward-Looking Statements\n\nThis press release contains certain statements that may be deemed to be\n“forward-looking statements” within the federal securities laws, including\nthe safe harbor provisions under the Private Securities Litigation Reform Act\nof 1995. Statements that are not historical are forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933 and Section\n21E of the Securities Exchange Act of 1934. Forward-looking statements relate\nto future events or our future performance or future financial condition.\nThese forward-looking statements are not historical facts, but rather are\nbased on current expectations, estimates and projections about our company,\nour industry, our beliefs and our assumptions. Such forward-looking statements\ninclude, but are not limited to, statements regarding our or our management\nteam’s expectations, hopes, beliefs, intentions or strategies regarding the\nfuture, including for the products we may launch, the success those products\nmay have in the marketplace, such as Arbli™ and REZENOPY™, and our\nstrategies related to those products. In addition, any statements that refer\nto projections, forecasts or other characterizations of future events or\ncircumstances, including any underlying assumptions, are forward-looking\nstatements. In some cases, you can identify forward-looking statements by the\nfollowing words: “anticipate,” “believe,” “continue,” “could,”\n“estimate,” “expect,” “intend,” “may,” “ongoing,”\n“plan,” “potential,” “predict,” “project,” “should,” or\nthe negative of these terms or other similar expressions, but the absence of\nthese words does not mean that a statement is not forward-looking.\nForward-looking statements are subject to a number of risks and uncertainties\n(some of which are beyond our control) that may cause actual results or\nperformance to be materially different from those expressed or implied by such\nforward-looking statements. Accordingly, readers should not place undue\nreliance on any forward-looking statements. These risks include risks relating\nto agreements with third parties; our ability to raise funding in the future,\nas needed, and the terms of such funding, including potential dilution caused\nthereby; our ability to continue as a going concern; security interests under\ncertain of our credit arrangements; our ability to maintain the listing of our\ncommon stock on the Nasdaq Stock Market LLC; claims relating to alleged\nviolations of intellectual property rights of others; the outcome of any\ncurrent legal proceedings or future legal proceedings that may be instituted\nagainst us; unanticipated difficulties or expenditures relating to our\nbusiness plan; and those risks detailed in our most recent Annual Report on\nForm 10-K, as amended, and subsequent reports filed with the Securities and\nExchange Commission.\n\nForward-looking statements speak only as of the date they are made. Scienture\nHoldings, Inc. undertakes no obligation to update or revise any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise that occur after that date, except as otherwise provided\nby law.\n\nContact:\n\nSCIENTURE HOLDINGS, INC.\n20 Austin Blvd\nCommack, NY 11725\nEmail: IR@Scienture.com\n\n Scienture Holdings, Inc. formerly TRxADE HEALTH, INC.\nCondensed Consolidated Balance Sheets\nAs of June 30, 2026 and December 31, 2025\n(Unaudited)\n\n June 30, 2026 December 31, 2025 \n ASSETS \n Current assets: \n Cash and cash equivalents $ 8,188,140 $ 6,662,008 \n Accounts receivable, net 385,313 731,328 \n Inventory 203,074 213,408 \n Prepaid expenses 425,370 262,278 \n Deferred offering costs - 47,384 \n Total current assets 9,201,897 7,916,406 \n Restricted cash 3,012,271 - \n Property, plant and equipment, net 14,500 15,500 \n Notes receivable 5,000,000 5,000,000 \n Interest receivable 437,500 250,000 \n Intangible assets, net 70,065,371 70,973,064 \n Operating lease right-of-use assets 2,468 23,360 \n Total assets $ 87,734,007 $ 84,178,330 \n \n LIABILITIES AND STOCKHOLDERS’ EQUITY \n Current liabilities: \n Accounts payable $ 916,771 $ 1,443,266 \n Accrued liabilities 503,634 657,034 \n Operating lease liability - current 2,546 24,137 \n Warrant liability - 10,914 \n Note payable, net of debt discount - current portion 1,118,349 - \n Development agreement liability - current portion 485,000 600,000 \n Total current liabilities 3,026,300 2,735,351 \n Note payable, net of debt discount 9,568,586 - \n Development agreement liability - 285,000 \n Deferred tax liability 11,037,595 11,037,595 \n Total liabilities 23,632,481 14,057,946 \n \n Commitments and contingencies (Note 13) \n \n Stockholders’ equity: \n Series A preferred stock, $0.00001 par value; 0 and 9,211,246 shares authorized; 0 shares issued and outstanding as of both June 30, 2026 and December 31, 2025 - - \n Series B preferred stock, $0.00001 par value; 787,754 shares authorized; 15,759 shares issued and outstanding as of both June 30, 2026 and December 31, 2025 - - \n Series C preferred stock, $0.00001 par value; 1,000 shares authorized; 0 shares issued and outstanding as of both June 30, 2026 and December 31, 2025 - - \n Series X preferred stock, $0.00001 par value; 9,211,246 shares authorized; 0 shares issued and outstanding as of both June 30, 2026 and December 31, 2025 - - \n \n Common stock, $0.00001 par value; 100,000,000 shares authorized; 41,064,146 and 40,630,815 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively 1,448,331 and 1,015,000 shares unvested as of June 30, 2026 and December 31, 2025, respectively 410 406 \n Additional paid-in capital 150,876,988 150,671,215 \n Accumulated deficit (86,775,872 ) (80,551,237 ) \n Total stockholders’ equity 64,101,526 70,120,384 \n Total liabilities and stockholders’ equity $ 87,734,007 $ 84,178,330 \n\nScienture Holdings, Inc. formerly TRxADE HEALTH, INC.\nCondensed Consolidated Statements Of Operations\nFor the Three and Six Months Ended June 30, 2026 and 2025\n(Unaudited)\n\n \n Three Months Ended Six Months Ended \n June 30, June 30, \n 2026 2025 2026 2025 \n Revenues $ 343,639 $ - $ 399,964 $ 10,258 \n Cost of sales 7,860 - 10,335 9,585 \n Gross profit 335,779 - 389,629 673 \n \n Operating expenses: \n Wage and salary expense 411,411 773,739 831,419 1,469,807 \n Professional fees 963,752 209,763 1,896,304 622,613 \n Accounting and legal expense 117,815 381,683 443,993 852,508 \n Technology expense 7,139 21,408 22,902 83,028 \n General and administrative 368,790 2,927,764 1,443,654 4,283,712 \n Research and development 1,166,605 843,549 1,960,589 1,418,228 \n Total operating expenses 3,035,512 5,157,906 6,598,861 8,729,896 \n Operating loss (2,699,733 ) (5,157,906 ) (6,209,232 ) (8,729,223 ) \n \n Non-operating income (expense): \n Change in fair value of warrant liability - 76,122 10,910 722,108 \n Change in fair value of derivative liability - (662,916 ) - (59,594 ) \n Loss on conversion of note payable - - - (96,646 ) \n Loss on disposition of subsidiaries - (385,528 ) - (385,528 ) \n Interest income 147,147 63,148 280,491 88,590 \n Interest expense (269,785 ) (653,493 ) (306,804 ) (1,324,277 ) \n Total non-operating expense (122,638 ) (1,562,667 ) (15,403 ) (1,055,347 ) \n \n Benefit (provision) for income taxes - - - - \n Net loss $ (2,822,371 ) $ (6,720,573 ) $ (6,224,635 ) $ (9,784,570 ) \n \n Net loss per common share \n Basic $ (0.07 ) $ (0.48 ) $ (0.16 ) $ (0.83 ) \n Diluted $ (0.07 ) $ (0.48 ) $ (0.16 ) $ (0.83 ) \n Weighted average common shares outstanding \n Basic 39,615,815 14,141,443 39,615,815 11,844,024 \n Diluted 39,615,815 14,141,443 39,615,815 11,844,024 \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1f177940-bb59-4f95-a316-0ca68e549ea4)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-14T12:08:00.366628447Z","server_sent_at_ms":1786709280366},"received_at":"2026-08-14T12:08:00.517Z","source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345299/0/en/scienture-reports-q2-2026-results-with-approximately-510-sequential-revenue-growth-from-q1-2026-and-significant-improvement-in-operating-performance.html"},"analysis":{"id":"108337","press_release_id":"119348","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["Q2 revenue remains nominal at $343,639 despite high percentage growth","Accumulated deficit stands at $86.8 million","Net loss of $2.8 million persists despite cost reductions"],"eventType":"earnings","narrative":"Scienture reported Q2 2026 revenue of $343,639, a 510% increase from the prior quarter, with gross margins expanding to 97.7%.\n\nOperating expenses decreased 41% year-over-year to approximately $3.0 million, narrowing the net loss by 58% to $2.8 million.\n\nThe company commenced the commercial launch of REZENOPY and ended the quarter with $11.2 million in cash and restricted cash.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Commercial launch of REZENOPY and 510% sequential revenue growth signal operating inflection for Scienture."},"keyFigures":{"revenue":343639,"customDimensions":{"gross_margin":"97.7%","gross_profit":335779,"operating_expenses":3035512,"cash_and_restricted_cash":"$11.2 million","sequential_revenue_growth":"510%"}},"quotedText":"We believe our second-quarter results demonstrate that Scienture has reached an important inflection point.","namedEntities":{"people":[{"name":"Narasimhan Mani","role":"President, Interim CFO, and Co-CEO"},{"name":"Shankar Hariharan","role":"Executive Chairman and co-CEO"}],"products":["REZENOPY","Arbli"],"companies":[{"name":"Scienture Holdings, Inc.","ticker":"SCNX"}],"dollarAmounts":[{"amount":"$343,639","context":"Q2 2026 revenue"},{"amount":"$11.2 million","context":"cash, cash equivalents and restricted cash as of June 30, 2026"},{"amount":"$3.0 million","context":"Q2 2026 operating expenses"},{"amount":"$2.7 million","context":"Q2 2026 operating loss"},{"amount":"$2.8 million","context":"Q2 2026 net loss"}]},"materialImpact":{"score":4,"reasoning":"Scienture reported a 510% sequential revenue surge to $343,639 and commenced the commercial launch of its second product, REZENOPY, marking an operational inflection point. Gross margins expanded to nearly 98% while operating expenses dropped 41% year-over-year, significantly narrowing net losses and strengthening the cash position."},"tickerRelevance":{"others":[],"primary":"SCNX"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":["product_launch"],"importanceComponents":{"tickerTier":"small-micro-cap","eventGravity":"operational-inflection","absoluteRevenueScale":"low"}},"event_type":"earnings","event_type_secondary":["product_launch"],"sentiment":"bullish","material_impact_score":4,"narrative":"Scienture reported Q2 2026 revenue of $343,639, a 510% increase from the prior quarter, with gross margins expanding to 97.7%.\n\nOperating expenses decreased 41% year-over-year to approximately $3.0 million, narrowing the net loss by 58% to $2.8 million.\n\nThe company commenced the commercial launch of REZENOPY and ended the quarter with $11.2 million in cash and restricted cash.","key_figures":{"revenue":343639,"customDimensions":{"gross_margin":"97.7%","gross_profit":335779,"operating_expenses":3035512,"cash_and_restricted_cash":"$11.2 million","sequential_revenue_growth":"510%"}},"named_entities":{"people":[{"name":"Narasimhan Mani","role":"President, Interim CFO, and Co-CEO"},{"name":"Shankar Hariharan","role":"Executive Chairman and co-CEO"}],"products":["REZENOPY","Arbli"],"companies":[{"name":"Scienture Holdings, Inc.","ticker":"SCNX"}],"dollarAmounts":[{"amount":"$343,639","context":"Q2 2026 revenue"},{"amount":"$11.2 million","context":"cash, cash equivalents and restricted cash as of June 30, 2026"},{"amount":"$3.0 million","context":"Q2 2026 operating expenses"},{"amount":"$2.7 million","context":"Q2 2026 operating loss"},{"amount":"$2.8 million","context":"Q2 2026 net loss"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-14T13:12:38.302Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-micro-cap","eventGravity":"operational-inflection","absoluteRevenueScale":"low"}},"durationMs":313855,"modelName":"glm-4.7"}}